{"brief_title": "Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx", "brief_summary": "RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells. PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.", "detailed_description": "OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor. OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks. PROJECTED ACCRUAL: Not specified", "condition": ["Precancerous Condition"], "intervention_type": ["Biological"], "intervention_name": ["autologous tumor cell vaccine"], "criteria": "DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx requiring surgery at least 4 times per year Condition must have existed for more than 1 year PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics", "gender": "All", "minimum_age": "1 Year", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "lung papilloma", "mesh_term": ["Papilloma", "Precancerous Conditions", "Vaccines"], "id": "NCT00002454"}